Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy
Shu-Hui Lv,Wang-Zhong Li,Hu Liang,Guo-Ying Liu,Wei-Xiong Xia,Yan-Qun Xiang
DOI: https://doi.org/10.2147/JIR.S310017
IF: 4.5
2021-05-26
Journal of Inflammation Research
Abstract:Shu-Hui Lv, 1– 3, * Wang-Zhong Li, 1, 2, * Hu Liang, 1, 2 Guo-Ying Liu, 1, 2 Wei-Xiong Xia, 1, 2 Yan-Qun Xiang 1, 2 1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, China; 2 Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, China; 3 Medical Affairs Office, The Fifth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China *These authors contributed equally to this work Correspondence: Yan-Qun Xiang; Wei-Xiong Xia Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China Tel\Fax +86-1866-6096-623 Email ; Purpose: We sought to assess the prognostic and predictive value of a circulating inflammation signature (CISIG) and develop CISIG-based tools for predicting prognosis and guiding individualized induction chemotherapy (ICT) in non-metastatic nasopharyngeal carcinoma (NPC). Patients and Methods: We retrospectively collected a candidate inflammatory biomarker panel from patients with NPC treated with definitive radiotherapy between 2012 and 2017. We developed the CISIG using candidate biomarkers identified by a least absolute shrinkage and selection operator (LASSO) Cox regression model. The Cox regression analyses were used to evaluate the CISIG prognostic value. A CISIG-based prediction model was constructed, validated, and assessed. Potential stratified ICT treatment effects were examined. Results: A total of 1149 patients were analyzed. Nine biomarkers selected by LASSO regression in the training cohort were used to construct the CISIG, including hyaluronidase, laminin, procollagen III, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, high-density lipoprotein, lactate dehydrogenase, and C-reactive protein-to-albumin ratio. CISIG was an independent prognostic factor for disease-free survival (DFS; hazard ratio: 2.65, 95% confidence interval: 1.93– 3.64; P − 0.2) was associated with worse 3-year DFS than low CISIG group in both the training (67.5% vs 88.3%, P < 0.001) and validation cohorts (72.3% vs 85.1%, P < 0.001). We constructed and validated a CISIG-based nomogram, which showed better performance than the clinical stage and Epstein–Barr virus DNA classification methods. A significant interaction between CISIG and the ICT treatment effect was observed ( P for interaction = 0.036). Patients with high CISIG values did not benefit from ICT, whereas patients with low CISIG values significantly benefited from ICT. Conclusion: The developed CISIG, based on a circulating inflammatory biomarker panel, adds prognostic information for patients with NPC. The proposed CISIG-based tools offer individualized risk estimation to facilitate suitable ICT candidate identification. Keywords: nasopharyngeal carcinoma, inflammatory biomarkers, circulating inflammation signature, prognostic value, predictive value, induction chemotherapy Nasopharyngeal carcinoma (NPC) is a malignancy arising from the nasopharyngeal epithelia. 1 The past decades have witnessed remarkable progress in imaging modalities and radiotherapy techniques. Non-metastatic NPC has become a highly curable disease, especially in patients with early-stage NPC. However, 70–80% of NPC patients are not diagnosed until they have progressed to advanced disease stages. 2 In the era of intensity-modulated radiotherapy (IMRT), induction chemotherapy (ICT) combined with concurrent chemoradiotherapy (CCRT) has emerged as the standard treatment strategy for patients with advanced-stage NPC. 3–5 Current clinical decision-making for NPC is determined primarily according to the anatomical-based tumor node metastasis (TNM) stage. 6 However, this strategy is insufficient for predicting survival outcomes or treatment benefits and cannot reflect the cancer properties that drive biological aggressiveness and metastatic potential. 1 Patients with identical TNM stages who are treated with the same standard care could present heterogeneous survival outcomes. Identifying those patients who are most suitable for intensified ICT would allow for the early modification of treatment strategies, which is vital for maximizing the curative benefits, -Abstract Truncated-
immunology